logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Class
    3. Substance P/Neurokinin-1 Receptor Antagonist

    Substance P/Neurokinin-1 Receptor Antagonist class drugs

    FiltersReset Filters
    5 results

    • akynzeo

      (Netupitant and Palonosetron)
      Helsinn Therapeutics (U.S.), Inc.
      Usage: AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing initial and repeat courses of highly emetogenic cancer chemotherapy, used in combination with dexamethasone. It consists of palonosetron and netupitant (or fosnetupitant in injectable form).

    • aponvie

      (APREPITANT)
      Heron Therapeutics, Inc.
      Usage: APONVIE is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. It is not studied for treating already established nausea and vomiting.

    • aprepitant

      (Aprepitant)
      Glenmark Pharmaceuticals Inc., USA
      Usage: Aprepitant is indicated for preventing chemotherapy-induced nausea and vomiting (CINV) in patients aged 12 and older undergoing highly or moderately emetogenic chemotherapy, and for preventing postoperative nausea and vomiting (PONV) in adults. It is not intended for treating established nausea and vomiting.

    • cinvanti

      (aprepitant)
      Heron Therapeutics, Inc.
      Usage: CINVANTI is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing highly and moderately emetogenic cancer chemotherapy, used in combination with other antiemetics and in specific dosing regimens. It is not studied for treating established nausea and vomiting.

    • varubi

      (rolapitant)
      TerSera Therapeutics LLC
      Usage: VARUBI® is indicated for the prevention of delayed nausea and vomiting in adults undergoing emetogenic cancer chemotherapy, in combination with other antiemetic agents. This includes initial and repeat courses of highly emetogenic chemotherapy.